Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk

Launched by ASAN MEDICAL CENTER · Jun 23, 2015

Keywords

ClinConnect Summary

Statin therapy improves coronary flow reserve (CFR) and decreases cardiac morbidity and mortality in patients with coronary artery disease (CAD) and hypercholesterolemia via pleiotropic effects of statins, including regression of atheroma, stabilization of atherosclerotic plaques. Lipid lowering with a statin also provided beneficial effects in hypertensive patients with average levels of serum total cholesterol in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Improvements in endothelial dysfunction and CFR may be related to the beneficial effects of statins ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Controlled Hypertension: treated SBP\<140 mmHg and DBP\<90 mmHg with angiotensin receptor blocker (ACE inhibitor) and/or calcium channel blocker LDL cholesterol ≥ 130mg/dL
• • Patients with statin-naive state, defined as receiving no statin therapy for more than 6 months during the previous 12 months.
• • Any 1 of these cardiovascular risk factors required: smoking, age over 55 (men) or 65 (women), history of cerebrovascular event, family history of early coronary heart disease before age 55, HDL cholesterol \< 40 mg/dL
• • The patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the Institutional Review Board
• Exclusion Criteria:
• • A previous history of intolerance or hypersensitivity to statins
• • Uncontrolled hypertension; SBP≥140 mmHg or DBP≥90 mmHg
• • Previous myocardial infarction or currently treated angina pectoris
• • Stroke, transient ischemic attack \< 3 months
• • Secondary hypertension
• • Diabetes mellitus
• • Peripheral vascular disease
• • Fasting serum triglyceride \> 500 mg/dL
• • Clinical congestive heart failure
• • Uncontrolled arrhythmia
• • Left ventricular hypertrophy: LV mass index \>134g/m2 (male) or \>110g/m2 (female)
• • Concomitant clinically important hematological, gastrointestinal, hepatic, renal or other disease
• • Pregnant or lactating women and those of child-bearing potential
• • Unwillingness or inability to comply with the procedures described in this protocol